Literature DB >> 33556606

Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models.

Maofan Zhang1, C Tilden Hagan2, Hayley Foley3, Xi Tian3, Feifei Yang4, Kin Man Au3, Yu Mi3, Yusra Medik3, Kyle Roche3, Kyle Wagner3, Zachary Rodgers5, Yuanzeng Min6, Andrew Z Wang7.   

Abstract

Chemoradiotherapy with cisplatin and etoposide is a curative management regimen for both small and non-small cell lung cancers. While the treatment regimen is effective, it also has a high toxicity profile. One potential strategy to improve the therapeutic ratio of chemoradiation is to utilize nanotherapeutics. Nanoparticle formulation of cisplatin and etoposide, however, is challenging due to the significant mismatch in chemical properties of cisplatin and etoposide. Herein we report the formulation of a polymeric nanoparticle formulation of cisplatin and etoposide using a prodrug approach. We synthesized a hydrophobic platinum prodrug, which was then co-delivered with etoposide using a nanoparticle. Using mouse models of lung cancer, we demonstrated that dual-drug loaded nanoparticles are significantly more effective than small molecule chemotherapy in chemoradiotherapy. These results support further investigation of nanoparticle-based drug formulations of combination chemotherapies and the use of nanotherapeutics in chemoradiotherapy. STATEMENT OF SIGNIFICANCE: The treatment of lung cancer often involves a combination of chemotherapy and radiation. While it can be effective, it also has a high toxicity profile. Preferential delivery of chemotherapeutics to the tumor while avoiding normal tissue would improve efficacy and lower toxicity. While this is challenging with conventional drug delivery technologies, nanotechnology offers a unique opportunity. In this study, we have engineered nanoparticles that are loaded with combination chemotherapeutics and showed such nanotherapeutics are more effective and less toxic than free chemotherapeutics in chemoradiotherapy. Our work highlights the importance and potential of nanoformulations of combination chemotherapy in chemoradiotherapy and cancer treatment. This approach can be translated clinically and it can have a significant impact on cancer treatment.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Chemoradiotherapy; Combination drug delivery; Lung cancer; Nanomedicine; Nanoparticle

Mesh:

Substances:

Year:  2021        PMID: 33556606      PMCID: PMC9083847          DOI: 10.1016/j.actbio.2021.02.001

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   10.633


  50 in total

1.  A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.

Authors:  Haihua Xiao; Haiqin Song; Qiang Yang; Haidong Cai; Ruogu Qi; Lesan Yan; Shi Liu; Yonghui Zheng; Yubin Huang; Tongjun Liu; Xiabin Jing
Journal:  Biomaterials       Date:  2012-06-22       Impact factor: 12.479

Review 2.  Chemotherapy advances in small-cell lung cancer.

Authors:  Bryan A Chan; Jermaine I G Coward
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 3.  50 Years of progress in the systemic therapy of non-small cell lung cancer.

Authors:  Heather Wakelee; Karen Kelly; Martin J Edelman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

4.  Progress in Nanomedicine: Approved and Investigational Nanodrugs.

Authors:  C Lee Ventola
Journal:  P T       Date:  2017-12

5.  Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.

Authors:  J J Muscato; C Cirrincione; G Clamon; M C Perry; G Omura; I Berkowitz; T Reid; J E Herndon; M R Green
Journal:  Lung Cancer       Date:  1995-12       Impact factor: 5.705

6.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 7.  Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.

Authors:  François L Reboul
Journal:  Hematol Oncol Clin North Am       Date:  2004-02       Impact factor: 3.722

8.  Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.

Authors:  David R Gandara; Kari Chansky; Kathy S Albain; Bryan R Leigh; Laurie E Gaspar; Primo N Lara; Howard Burris; Paul Gumerlock; J Philip Kuebler; James D Bearden; John Crowley; Robert Livingston
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

9.  Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo.

Authors:  Feifei Yang; Yusra Medik; Liantao Li; Xi Tian; Dong Fu; Kim L R Brouwer; Kyle Wagner; Bo Sun; Hossein Sendi; Yu Mi; Andrew Z Wang
Journal:  Small       Date:  2020-01-23       Impact factor: 13.281

10.  Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group.

Authors:  R Arriagada; A Kramar; T Le Chevalier; H De Cremoux
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

View more
  5 in total

1.  3D printed drug-loaded implantable devices for intraoperative treatment of cancer.

Authors:  C Tilden Hagan; Cameron Bloomquist; Samuel Warner; Nicole M Knape; Isaiah Kim; Hayley Foley; Kyle T Wagner; Sue Mecham; Joseph DeSimone; Andrew Z Wang
Journal:  J Control Release       Date:  2022-02-22       Impact factor: 11.467

Review 2.  Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review.

Authors:  Adrian Emilian Bădilă; Dragoș Mihai Rădulescu; Adelina-Gabriela Niculescu; Alexandru Mihai Grumezescu; Marius Rădulescu; Adrian Radu Rădulescu
Journal:  Cancers (Basel)       Date:  2021-08-23       Impact factor: 6.639

Review 3.  Cisplatin for cancer therapy and overcoming chemoresistance.

Authors:  Ranmali Ranasinghe; Michael L Mathai; Anthony Zulli
Journal:  Heliyon       Date:  2022-09-14

Review 4.  Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy.

Authors:  Eliza Rocha Gomes; Marina Santiago Franco
Journal:  Pharmaceutics       Date:  2022-01-03       Impact factor: 6.321

5.  Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of in vivo lung cancer animal model.

Authors:  Tian Zhong; Xingren Liu; Hongmin Li; Jing Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.